<DOC>
	<DOCNO>NCT01011868</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability BI 10773 two different dos compare placebo long term treatment ( 78 week ) combination basal insulin patient type 2 diabetes mellitus insufficient glycaemic control .</brief_summary>
	<brief_title>Efficacy Safety BI 10773 Combination With Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed date write informed consent date Visit 1 accordance Good Clinical Practice ( GCP ) local legislation 2 . Male female patient diagnosis Type 2 Diabetes Mellitus treat stable dose basal insulin without concomitant metformin / sulfonylurea . 3 . Glycosylated hemoglobin A1c ( Type A , subtype 1c ) &gt; 7.0 % &lt; = 10 % Visit 1 ( screen ) 4 . Suitability trial participation accord investigator 's judgment ( evaluate alternative treatment option consideration patient complete study ) 5 . Age &gt; =18 year Visit 1 ( screen ) 6 . BMI &lt; = 45 kg/m2 ( Body Mass Index ) Visit 1 ( screen ) Exclusion criterion : 1 . Patients poorly control hyperglycemia 2 . Frequent ( discretion investigator ) episodes hypoglycemic event basal insulin therapy 3 . MI , stroke , TIA within 3 month prior obtain inform consent 4 . Impaired hepatic renal function ; gastric surgery ; cancer within last 5 year ; blood dyscrasia 6 . Treatment antidiabetic , antiobesity medication , steroid thyroid hormone , participation another trial investigational drug 7 . Premenopausal woman insufficient birth control 8 . Alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>